The Fund seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Clinical Trials Index, which tracks the performance of select clinical trials stage biotechnology companies.Effective February 27, this Fund's name changed from Virtus LifeSci Biotech Clinical Trials ETF to Virtus Biotech Clinical Trials ETF.
Virtus Biotech Clinical Trials ETF · Issued by Virtus
| TRAX | First Tracks Biotherapeutics Inc | 1.48% |
| AMLX | Amylyx Pharmaceuticals Inc | 1.44% |
| XNCR | Xencor Inc | 1.38% |
| ABCL | AbCellera Biologics Inc Ordinary Shares | 1.36% |
| MNPR | Monopar Therapeutics Inc | 1.17% |
| ATAI | AtaiBeckley Inc | 1.17% |
| QURE | uniQure NV | 1.10% |
| MBX | MBX Biosciences Inc | 1.08% |
| REPL | Replimune Group Inc | 1.07% |
| SLS | SELLAS Life Sciences Group Inc | 1.06% |
No recent news for BBC. The ingest cron pulls every 15 minutes during market hours.